Concretely: 96.4% · VendorInvestigate · 97.9%.
I think I have a problem. I am not yet sure whether it is a real problem or a measurement artefact.
I want to know whether this is recoverable or whether the honest answer is to write it off.
How do I distinguish the benign explanation from the one that matters?
1.5 percentage points, and the direction is the informative half. VendorInvestigate reports 96.4 per cent and the certificate 97.9, so the independent figure is lower. As impurity that is 3.6 per cent against 2.1 — 1.71 times as much unassigned area. A gentler gradient resolves impurities that a steeper one hides beneath the main peak, so the better method routinely reports the worse number; 1.5 points is comfortably inside what method choice alone produces on identical material. Ask both parties for the method section before you decide which figure is wrong, because the answer is often neither.
The short answer is that two competent laboratories on identical material will disagree, and the disagreement is almost always explainable by method differences.
Temperature affects the dynamics of molecular conformation, and if a peptide has proline residues that interconvert on the chromatographic timescale, the peak will split or shoulder at low temperature and collapse at high temperature.
Mobile phase additive choice affects ionisation and peak shape — TFA gives sharp peaks but suppresses mass spectrometry signal, formic acid gives worse peaks but preserves signal.
The ICH Q3A impurity thresholds and the relevant pharmacopoeial chapters all specify method validation requirements that almost no research-grade certificate claims to meet.
One qualification: achieving purity above roughly 98 per cent on a 30-residue peptide is fighting the chemistry of synthesis, not the quality of the purification.
Compare purity within a single laboratory on the same method, never across laboratories.
Aggregated, published test results and vendor ratings built from submitted batches. Methodology stated, dataset browsable, no listing fees.
Browse resultsGradient slope is the most powerful parameter and almost nobody mentions it, which is why two reports on the same material disagree by a point.
Buffer versus acid in the mobile phase changes the ionisation state of basic and acidic residues, shifting retention and selectivity — same vial, potentially different separation.
Sample solvent strength affects peak shape — if you inject in strong solvent on a gradient starting in weak solvent, the solvent peak can distort your main peak or create a false shoulder.
Inter-laboratory studies on identical peptide material routinely find half-a-per-cent to a full-per-cent spreads in reported purity on the same sample.
The practical summary: ask for the chromatogram and the method, and ignore the headline number until you have both.
Reporting threshold is convention and not chemistry, which is why two certificates with different thresholds disagree by a tenth of a point or more.
Detection wavelength matters because 214 nm sees the peptide backbone while 280 nm sees only aromatic side chains — so truncation impurities lacking a tryptophan are invisible at 280 nm.
The fraction of your main peak that is actually your target versus isomers, fragments or related sequences is invisible without complementary identity testing.
Proline conformer interconversion kinetics are well-characterised and the half-life is of the same order as the chromatographic peak width at room temperature.
If you are ranking vendors, specify a method and have all samples tested at the same place.
edited 21 Jul 2025 by gel_pack_warm — updated for the 2026 guidance change
Area percentage is not mass percentage, and conflating the two is the most common misreading of a purity figure.
Column pore size affects mass transfer — a 100 Angstrom packing on a 5 kDa peptide restricts diffusion, broadening the peak and potentially hiding small impurities in the shoulders.
Published side-by-side method comparisons show that a two-point difference in purity on the same vial is easily explained by method choice alone.
Worth noting that method standardisation is poor in the research-grade space compared to pharmaceutical work, so identical-looking methods can produce different results.
If you only pay for one test, pay for quantified content. Purity is the number everyone quotes and content is the number that changes what you do.
The relevant detail is that the method matters more than the vial, which is why specifying a method buys you far more than changing suppliers does.
Gradient slope controls resolution, and gentler slopes resolve co-eluting impurities into separate peaks — so the better method reports the worse purity number.
In practice: ask for the chromatogram, check the method section, check the lot number against the vial, and set your accept threshold before you see the result rather than after.
Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.